Fanying Meng, 64830 47Th Ave, San Francisco, CA 94121

6670364, Dec 30, 2003

Jan 29, 2002

10/060967

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya

A61P 2900

51425304, 514303, 5142342, 51425211, 514218, 540575, 544127, 544121, 544362, 544357, 546120

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

6677365, Jan 13, 2004

Mar 25, 2002

10/106881

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd.

A61K 3142

514379, 514301, 514302, 514303, 514367, 514394, 514405, 546114, 546115, 546118, 546120, 548180, 548217, 5483044, 5483611

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

6809113, Oct 26, 2004

Feb 27, 2002

10/087208

Edgardo Laborde - Foster City CA
Louise Robinson - San Carlos CA
Fanying Meng - San Francisco CA
Brian T. Peterson - San Francisco CA
Hugo O. Villar - La Jolla CA
Steven E. Anuskiewicz - San Bruno CA
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co. - Nagoya

A61K 3135

514456, 514256, 514337, 514356, 514363, 549 60, 549366, 548136, 548146, 548204, 548253, 548254, 5462827, 544333, 544335

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohns disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

6962926, Nov 8, 2005

Aug 8, 2003

10/637746

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - Mountain View CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Wenli Ma - Mountain View CA, US
Yukiharu Matsumoto - Gifu, JP
Kunihisa Baba - Yokkaichi, JP
Hideaki Inagaki - Inabe, JP
Katsumasa Tanaka - Inabe, JP
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Masayuki Okamoto - Tokyo-to, JP
Takashi Nakamura - Kuwana, JP
Atsushi Miyachi - Kuwana, JP
Mitsuaki Takeuchi - Inabe, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co., Ltd. - Nagoya

A61K031/437
A61K031/496
C61K031/5377
C07D471/04
A61P029/00

514303, 51421707, 5142342, 51425304, 546120, 546119, 544127, 544362, 540597, 540599

Compounds of formula A and formula B: and their pharmaceutically acceptable salts, compositions comprising them, methods for their use, and their use in the preparation of medicaments. The compounds are antagonists of MCP-1 function, and are useful in the prevention and treatment of chronic or acute inflammatory or autoimmune diseases, such as multiple sclerosis, and in the prevention and treatment of allergic hypersensitivity disorders.

6992086, Jan 31, 2006

Nov 17, 2003

10/716363

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - San Francisco CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA

A61K 31/496
A61K 31/437
C07D 498/04
C07D 471/04
A61P 37/00

51425304, 514302, 5142342, 514303, 51425211, 514218, 540575, 544127, 544362, 544121, 544357, 546115, 546120

The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

6998407, Feb 14, 2006

Nov 18, 2003

10/716652

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - San Francisco CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co. Ltd. - Nagoya

A61K 31/36
A61K 31/343
C07D 307/79
C07D 317/60

514301, 514302, 514440, 514443, 514465, 514466, 514469, 546114, 546115, 549 15, 549 57, 549436, 549462, 549466, 549468, 549470

Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

7297696, Nov 20, 2007

Oct 19, 2004

10/969440

Edgardo Laborde - Foster City CA, US
Louise Robinson - San Carlos CA, US
Fanying Meng - San Francisco CA, US
Brian T. Peterson - San Francisco CA, US
Hugo O. Villar - La Jolla CA, US
Steven E. Anuskiewicz - San Bruno CA, US
Yoshiro Ishiwata - Aichi-gun, JP
Shoji Yokochi - Inabe-gun, JP
Yukiharu Matsumoto - Gifu, JP
Takuji Kakigami - Inabe-gun, JP
Hideaki Inagaki - Anjoh, JP
Takahito Jomori - Nagoya, JP
Kouji Matsushima - Matsudo, JP

Telik, Inc. - Palo Alto CA
Sanwa Kagaku Kenkyusho Co. - Nagoya

A61K 31/498
C07D 241/36

514249, 544353

Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephrtitis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

6506739, Jan 14, 2003

May 1, 2001

09/847533

R. Jason Herr - Voorheesville NY
Robert T. Lum - Palo Alto CA
Steven R. Schow - Redwood Shores CA
Fanying Meng - San Francisco CA
Michael R. Kozlowski - Poway CA
Pavel Zhichkin - Albany NY

Telik, Inc. - South San Francisco CA

A61K 31664

514140, 514141, 558170, 558171, 558177, 558178, 558195

Bis-(N,Nâ-bis-(2-haloethyl)amino)phosphoramidates, pharmaceutical compositions containing them, methods of treatment using them, and processes for their preparation. The compounds possess anti-tumor activities or are capable of being modified to have anti-tumor activities; and this invention relates to the use of the compounds in methods for the treatment of tumors and, especially, for the treatment of cancer.